Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
J Infect Dev Ctries ; 16(10): 1596-1601, 2022 10 31.
Artigo em Inglês | MEDLINE | ID: mdl-36332212

RESUMO

INTRODUCTION: Vaccine-preventable diseases can be effectively managed through timely vaccine booster doses. In this study, the tetanus vaccination status of healthcare professionals and their level of knowledge about tetanus vaccination were investigated. METHODOLOGY: The data were obtained through a survey questionnaire from 336 healthcare professionals. The survey participants were recruited on a voluntary basis among the personnel working in a tertiary hospital between 1 July 2021 and 30 September 2021. The participants were asked about their tetanus vaccination status and general awareness about the tetanus vaccine. RESULTS: The survey participants included nurses (41.4%, n = 139), doctors (39.9%, n = 134) and support unit personnel (18.8%, n = 63). The support unit personnel had insufficient knowledge about military service period, pregnancy period, vaccination of women aged 15-49 years, and the necessity of booster tetanus vaccine every 10 years. Interestingly, the nurses had significantly inadequate knowledge of geriatric tetanus vaccination. CONCLUSIONS: Although the tetanus immunization program is widely implemented throughout the country, our study concluded that it is necessary to educate healthcare professionals on the importance of the tetanus vaccine.


Assuntos
Tétano , Gravidez , Humanos , Feminino , Idoso , Tétano/prevenção & controle , Estudos Transversais , Turquia , Vacinação , Toxoide Tetânico , Atenção à Saúde
2.
Intern Emerg Med ; 16(8): 2139-2153, 2021 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-33728579

RESUMO

Peripheral lymphadenopathy (LAP) is an important and common abnormal finding of the physical exam in general medical practice. We aimed to reveal the LAP etiology and demographic, clinical and laboratory variables that may be useful in the differential evaluation of LAP. This multicenter, nested case-control study including 1401 patients between 2014 and 2019 was conducted in 19 tertiary teaching and research hospitals from different regions in Turkey. The ratio of infectious, malign and autoimmune/inflammatory diseases was 31.3%, 5% and 0.3%, respectively. In 870 (62%) of patients had nonspecific etiology. Extrapulmonary tuberculosis (n: 235, 16.8%) was the most frequent cause of LAP. The ratio of infective etiology of LAP was significantly lower in patients older than 65 years-old compared to younger patients with the rate of 66.67% and 83.84%, respectively (p 0.016, OR 0.386, 95% Cl 0.186-0.803). The probability of malign etiology was higher both in patients who are older than 45 years-old (p < 0.001, OR 3.23, 95% Cl 1.99-5.26) and older than 65 years-old (p 0.002, OR 3.36, 95% Cl 1.69-6.68). Age, localization and duration of LAP, leukocytosis, anemia, thrombocytopenia, CRP and sedimentation rate were important parameters to differentiate infections. Size of lymph node and splenomegaly in addition to the parameters above were useful parameters for differentiating malign from benign etiology. Despite the improvements in diagnostic tools, reaching a definite differential diagnosis of lymphadenopathy is still challenging. Our results may help clinicians to decide in which cases they need an aggressive workup and set strategies on optimizing the diagnostic approach of adulthood lymphadenopathy.


Assuntos
Linfadenopatia/complicações , Linfadenopatia/diagnóstico , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Estudos de Casos e Controles , Demografia/métodos , Demografia/estatística & dados numéricos , Diagnóstico Diferencial , Feminino , Febre/complicações , Febre/etiologia , Hepatomegalia/complicações , Hepatomegalia/etiologia , Humanos , Linfonodos/patologia , Linfadenopatia/epidemiologia , Masculino , Pessoa de Meia-Idade , Estudos Retrospectivos , Esplenomegalia/complicações , Esplenomegalia/etiologia , Tuberculose/complicações , Tuberculose/fisiopatologia , Turquia
3.
Health Qual Life Outcomes ; 14(1): 153, 2016 Nov 03.
Artigo em Inglês | MEDLINE | ID: mdl-27809934

RESUMO

BACKGROUND: The aim of this study was to assess health-related quality of life (HRQOL) among chronic hepatitis B (CHB) patients in Turkey and to study related factors. METHODS: This multicenter study was carried out between January 01 and April 15, 2015 in Turkey in 57 centers. Adults were enrolled and studied in three groups. Group 1: Inactive HBsAg carriers, Group 2: CHB patients receiving antiviral therapy, Group 3: CHB patients who were neither receiving antiviral therapy nor were inactive HBsAg carriers. Study data was collected by face-to-face interviews using a standardized questionnaire, Short Form-36 (SF-36) and Hepatitis B Quality of Life (HBQOL). Values equivalent to p < 0.05 in analyses were accepted as statistically significant. RESULTS: Four thousand two hundred fifty-seven patients with CHB were included in the study. Two thousand five hundred fifty-nine (60.1 %) of the patients were males. Groups 1, 2 and 3, consisted of 1529 (35.9 %), 1721 (40.4 %) and 1007 (23.7 %) patients, respectively. The highest value of HRQOL was found in inactive HBsAg carriers. We found that total HBQOL score increased when antiviral treatment was used. However, HRQOL of CHB patients varied according to their socio-demographic properties. Regarding total HBQOL score, a higher significant level of HRQOL was determined in inactive HBV patients when matched controls with the associated factors were provided. CONCLUSIONS: The HRQOL score of CHB patients was higher than expected and it can be worsen when the disease becomes active. Use of an antiviral therapy can contribute to increasing HRQOL of patients.


Assuntos
Hepatite B Crônica , Qualidade de Vida , Adulto , Idoso , Antivirais/uso terapêutico , Estudos Transversais , Feminino , Indicadores Básicos de Saúde , Hepatite B Crônica/tratamento farmacológico , Hepatite B Crônica/psicologia , Humanos , Entrevistas como Assunto , Masculino , Pessoa de Meia-Idade , Estudos Prospectivos , Turquia
4.
Hemodial Int ; 20(3): 358-61, 2016 07.
Artigo em Inglês | MEDLINE | ID: mdl-26346615

RESUMO

Catheter and/or arteriovenous (A-V) graft-related bacteremia is an important cause of morbidity and mortality among hemodialysis (HD) patients. Endocarditis, septic arthritis, epidural abscess, septic embolism, and osteomyelitis are the most common complications of catheter and/or A-V graft-related bacteremia; however, endogenous endophthalmitis is rarely seen. To the best of our knowledge, Enterococcus faecalis is the first case report in this population. We hereby report a case of endogenous endophthalmitis caused by E. faecalis as a complication of catheter and/or A-V graft-related bacteremia in a diabetic patient, who was undergoing HD for 5 years. We also discuss the etiology, clinical features, and outcomes of endogenous endophthalmitis in HD patients with a brief review of the literature. Although broad-spectrum parenteral (intravenous and intravitreal) antibiotics were used for 4 weeks, evisceration of the left eye could not be avoided. Endogenous endophthalmitis is a rare but rapidly blinding complication of catheter and/or A-V graft-related bacteremia in HD patients. It can develop as a result of silent catheter and/or A-V graft infections, which may lead to recurrent bacteremia. E. faecalis should be considered as a pathogen in this population who had recent history of catheter or A-V graft procedure.


Assuntos
Endoftalmite/etiologia , Enterococcus faecalis , Infecções por Bactérias Gram-Positivas/etiologia , Diálise Renal/efeitos adversos , Sepse/complicações , Dispositivos de Acesso Vascular/efeitos adversos , Feminino , Humanos , Pessoa de Meia-Idade
5.
Drug Des Devel Ther ; 8: 621-5, 2014.
Artigo em Inglês | MEDLINE | ID: mdl-24936126

RESUMO

OBJECTIVE: To analyze the effect of increasing Entecavir (ETV) dosage in patients with chronic hepatitis B (CHB) who partially responded to ETV after 1 year. METHODS: Twenty-three hepatitis B e antigen (HBeAg)-positive and 36 HBeAg-negative patients with CHB were treated with ETV 0.5 mg daily. After 1 year of the treatment, those with detectable hepatitis B virus (HBV-DNA) were randomized to either ETV 0.5 mg or 1 mg daily. The resistance to ETV was excluded. Both groups received ETV for 3 years. The groups were compared in aspects of undetectable DNA. RESULTS: Group 1 was given 0.5 mg ETV and included 32 patients (20 HBeAg-negative and 12 HBeAg-positive). Group 2 was given 1 mg ETV and consisted of 27 patients (16 HBeAg-negative and eleven HBeAg-positive). Group 2 had more effective suppression of HBV-DNA while both groups had comparable rates of HBeAg loss (58% and 63% for group 1 and group 2, respectively) and alanine transaminase (ALT) normalization at the end of 4 years. CONCLUSION: Increasing ETV dose from 0.5 mg to 1 mg after 1 year of ETV treatment may provide an effective suppression of viral replication.


Assuntos
Antivirais/administração & dosagem , Guanina/análogos & derivados , Vírus da Hepatite B/efeitos dos fármacos , Adulto , Antivirais/farmacologia , Relação Dose-Resposta a Droga , Guanina/administração & dosagem , Guanina/farmacologia , Humanos , Testes de Sensibilidade Microbiana , Pessoa de Meia-Idade , Relação Estrutura-Atividade , Replicação Viral/efeitos dos fármacos
6.
Turkiye Parazitol Derg ; 37(3): 212-5, 2013.
Artigo em Turco | MEDLINE | ID: mdl-24192626

RESUMO

Ascaris lumbricoides is a comman intestinal helminths in humans. It is a parasite which commonly affects society with a low socioeconomic status, especially in tropical and rural areas. Ascaris lumbricoides infestation can lead to serious complications because of the mobility of the worms. The parasite can cause a variety of complications like intestinal obstruction, perforation, biliary obstruction, pancreatitis, peritonitis, liver abscess, cholangiohepatitis, volvulus, and gangrene, etc. A 59-year-old female patient hospitalized with the diagnosis of mesenteric ischemia was operated on for jejunal resection. On the 6th postoperative day, a worm was noticed emerging through the nasogastric tube. Ascaris lumbricoides was determined as a result of the examination microbiology laboratory. The patient was treated successfully with one dose of albendazole 200 mg 1x2. Our case describes a clinical situation of ascariasis observed after jejunal resection and emphasizes the importance of remaining aware of this rare complication of ascariasis.


Assuntos
Ascaríase/diagnóstico , Ascaris lumbricoides/isolamento & purificação , Intubação Gastrointestinal/instrumentação , Isquemia/diagnóstico , Jejuno/cirurgia , Doenças Vasculares/diagnóstico , Albendazol/uso terapêutico , Animais , Antinematódeos/uso terapêutico , Ascaríase/complicações , Ascaríase/tratamento farmacológico , Feminino , Humanos , Isquemia/parasitologia , Isquemia Mesentérica , Pessoa de Meia-Idade , Doenças Vasculares/parasitologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...